HUS Pharmacy is searching for a new supplier of L-4-boronophenylalanine (synonyms: BPA, borofalan, 4-(borono- 10B)-L-phenylalanine), CAS No [80994-59-8]. The supplied BPA will be used in pharmaceutical preparation of BPA-fructose complex used in BNCT-treatment at HUS Comprehensive Cancer Centre. The aim of this RFI is to survey and identify suppliers with the capability to manufacture BPA on a scale and according to the medicinal grade specifications set by HUS Pharmacy. After this RFI HUS Pharmacy will conduct a formal tendering process to establish a multi-year supplier contract. The estimated consumption of BPA is 2-4 kilograms per year starting from 2028. This number can change, as the accelerator based BNCT treatment is a novel process and thus under constant clinical study and development. The specifications for BPA are set out in Attachment 1 to this notice. We ask the interested parties to provide as much as possible of the following information: •Approximate minimum and maximum size of order in grams or kilograms, when delivery is from a single production batch. •Approximate time from order to delivery to Finland. We acknowledge that the production of BPA requires several months to complete. •Shelf-life of product from batch release. If provider has an ongoing stability program to extend the shelf-life, then the expected future shelf-life information can also be noted. •Description of the quality assurance of the final product and quality management of the production process. •Any possible regulatory requirements regarding HUS Pharmacy when delivering boron-10 isotope to Finland, if the providers national regulations have such requirements. •Information about other possible boron-10 carriers available for BNCT treatment can be provided. The information can be provided in a format of your choice in English or Finnish. Responses provided by suppliers will be treated confidentially. Interested party can send questions regarding the RFI to HUS Pharmacy with...
This is one of 2 active Finland Pharmaceuticals opportunities most of your competitors will never see.
Your competitors are watching the same crowded contracts everyone else is. Track this opportunity and every one like it worldwide, set deadline alerts, and win where they aren’t. Free for 14 days, no card.
Start Free| Issuing agency | HUS Group, the Joint Authority for Helsinki and Uusimaa |
|---|
| Country | Finland |
|---|
| Category | Pharmaceuticals |
|---|
| Published | September 03, 2026 |
|---|
| Procurement stage | Request for Proposal (RFP) |
|---|
| Response due | Not specified / rolling |
|---|
| Status | Open — accepting responses |
|---|
| Official source | View original notice |
|---|
| Last verified | September 20, 2026 |
|---|
Source: Tenders Electronic Daily (TED), © European Union. Notice content reused under Commission Decision 2011/833/EU; editorial content licensed CC BY 4.0. GlobalGov is not affiliated with the European Union.
See every Finland Pharmaceuticals opportunity your competition is missing. Free for 14 days.
Get real-time alerts, competitive intelligence, and deadline tracking for this and every market worldwide.
Start Free Trial — No Card RequiredFree 14-day trial · no card required
See who is already competing here →Used by capture teams who win by looking where the big players aren’t.
Get a free Finland Pharmaceuticals intelligence report in your inbox
A personalized report on Finland Pharmaceuticals opportunities, emailed in 5-10 minutes. One per month, no account needed.